Complications and treatment of the myelodysplastic syndromes.
The major complications of the myelodysplastic syndromes (MDS) are related to cytopenia and evolution to acute myeloid leukemia (AML). Hematopoietic growth factors are only of limited benefit to alleviate the cytopenia. Therapy in MDS patients over the age of 50 should aim at prolonging survival while limiting the risk of toxicity. Those with stable disease should only receive supportive care; those with progressive cytopenia should have a trial with low-dose chemotherapy. Aggressive chemotherapy should only be reserved for those failing low-dose therapy. Therapy in MDS patients under the age of 50 should aim at cure of the disease. Although aggressive chemotherapy can induce complete remission in the majority of these patients, remission is usually short. Allogeneic bone marrow transplantation is probably the only curative option in these patients and should be the treatment of choice.
Tricot
G J
GJ
Department of Medicine, Indiana University Medical Center, Indianapolis.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000150:complications* / Q000628:therapy*; D011289:Preleukemia
D000970:Antineoplastic Agents